Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may guide heart failure treatment to cut hospital returns

NCT ID NCT02963272

Diagnosis Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

Heart failure is a serious condition with high death and rehospitalization rates. This study tested whether using a blood marker called ST2 to guide treatment could reduce hospital readmissions within one month. Researchers compared standard care with a strategy that adjusts medications based on ST2 levels in 123 hospitalized heart failure patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ST2 biomarker-guided treatment strategy
What this could lead to
If successful, this approach could help doctors personalize heart failure treatment to reduce hospital readmissions and lower healthcare costs.
What could go wrong
This is a small, completed study with 123 participants, so results may not apply to all heart failure patients. The ST2-guided strategy may not significantly reduce readmissions compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

123 people

The number who actually took part.

Started

Jan 2017

Finished

Apr 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Heart failure hospitalization Exclusion Criteria: * Other study * Pregnancy, feeding * Refusal * Not possible to perform information

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diastolic heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure Fibrosis heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diastolic heart failure Heart failure Systolic heart failure stage C

Contacts and locations

Locations

  • University Regional Hospital Arnaud de Villeneuve

    Montpellier, Languedoc-Roussillon, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.